The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Loss of the DNA repair gene RNase H2 and a unique subset of DDR-deficient leiomyosarcomas.
 
Michael Nakazawa
Research Funding - Repare Therapeutics (Inst)
 
Ian M. Silverman
Employment - Incyte; Repare Therapeutics
Stock and Other Ownership Interests - Incyte; Repare Therapeutics
 
Victoria Rimkunas
Employment - Repare Therapeutics
Leadership - Repare Therapeutics
Stock and Other Ownership Interests - Repare Therapeutics
 
Artur Veloso
Employment - Repare Therapeutics
Stock and Other Ownership Interests - Repare Therapeutics
Patents, Royalties, Other Intellectual Property - Repare Therapeutics
Travel, Accommodations, Expenses - Repare Therapeutics
 
Dominik Glodzik
Employment - Repare Therapeutics
Consulting or Advisory Role - Repare Therapeutics
Patents, Royalties, Other Intellectual Property - Repare Therapeutics
 
Shreyaskumar Patel
Consulting or Advisory Role - Adaptimmune; BioAtla; Daiichi Sankyo; Deciphera; GlaxoSmithKline; Rain Oncology
Research Funding - Blueprint Medicines (Inst); HUTCHMED (Inst); Rain Therapeutics (Inst)
 
Christina Lynn Roland
Consulting or Advisory Role - Lumanity
 
Pamela T. Soliman
Honoraria - Medscape
Consulting or Advisory Role - AADi; AADi; Amgen; Clovis Oncology; Eisai; GlaxoSmithKline; WebMD
Research Funding - Incyte (Inst); Novartis (Inst)
 
Hannah Beird
No Relationships to Disclose
 
Chia-Chin Wu
No Relationships to Disclose
 
Davis Ingram
No Relationships to Disclose
 
Rossana Lazcano Segura
No Relationships to Disclose
 
Khalida M Wani
No Relationships to Disclose
 
Alexander J. Lazar
Leadership - Archer; Iterion Therapeutics; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals; PAIGE.AI
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb; Deciphera; Novartis
Research Funding - AstraZeneca; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Timothy A. Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Dark Blue Therapeutics; Diffusion Pharmaceuticals; EMD Serono; F-Star; Genmab; Gerson and Lehrman Group; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; Idience; Ignyta; ImmuneSensor Therapeutics; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Natera; Nexys Therapeutics; Novocure; OncoSec; Ono Pharmaceutical; Oregon Health & Science University (OHSU); Pegascy; PER; Pfizer; Piper Sandler; ProLynx; Repare Therapeutics; resTORbio; Roche; Schrodinger; Terremoto Biosciences; Theragnostics; Varian Medical Systems; Versant Health; Vibliome Therapeutics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); ImmuneSensor Therapeutics (Inst); Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tesaro (Inst); Vivace Therapeutics (Inst); Zenith Epigenetics (Inst)
 
Wei-Lien Wang
No Relationships to Disclose
 
J Andrew Andrew Livingston
Consulting or Advisory Role - Foghorn Therapeutics
Research Funding - Repare Therapeutics (Inst)
Other Relationship - Guidepoint Global